Back to blog
    Breaking Study Updates

    VK2735 Phase 3 VANQUISH Program: Viking's Dual GIP/GLP-1 Agonist

    19 May 20269 min read

    Viking Therapeutics' VK2735 has reported up to 14.7% mean weight reduction at 13 weeks in the VENTURE Phase 2 trial, with the Phase 3 VANQUISH program now fully enrolled.

    VK2735 is a dual agonist of the GIP and GLP-1 receptors developed by Viking Therapeutics, with both subcutaneous weekly and oral daily formulations in clinical development. It is the most advanced non-Lilly dual incretin in the obesity pipeline.

    VENTURE Phase 2 (Subcutaneous)

    The 13-week VENTURE trial reported mean weight reduction of up to 14.7% from baseline in the highest dose cohort, published in Obesity in January 2026 [1]. No plateau was observed at week 13, consistent with continued response with longer treatment duration.

    VENTURE-Oral Phase 2

    Oral VK2735 produced up to 12.2% mean weight reduction over 13 weeks in dose-ranging Phase 2 data presented at the European Congress on Obesity 2026 [2]. The oral formulation is differentiated from peptide GLP-1 oral candidates by its small-molecule design.

    VANQUISH Phase 3

    The VANQUISH program comprises two registrational Phase 3 trials of subcutaneous VK2735:

    • VANQUISH-1: Adults with obesity, primary endpoint at 78 weeks
    • VANQUISH-2: Adults with obesity and type 2 diabetes, primary endpoint at 78 weeks

    Enrollment for VANQUISH-2 completed in March 2026 [3].

    Comparative Positioning

    VK2735 sits in the same mechanistic class as Tirzepatide (GIP and GLP-1 dual agonism). Researchers comparing the two compounds typically focus on receptor binding kinetics, downstream signalling bias, and body-mass trajectory differences in head-to-head preclinical work.

    Research Availability

    See the VK2735 research profile for receptor pharmacology, clinical-register status and citations, plus availability notifications. VK2735 is not currently distributed as a research-grade peptide. Comparative work in the dual incretin class is conducted with Tirzepatide, which remains the reference molecule for GIP/GLP-1 receptor research. Pair with Cagrilintide for amylin co-agonism work.

    References

    1. [1] Weekly Subcutaneous VK2735 VENTURE Phase 2 trial. Obesity (Silver Spring). 2026;34(3):537-549.
    2. [2] Viking Therapeutics ECO 2026 oral VK2735 poster presentation.
    3. [3] Viking Therapeutics press release, 26 March 2026: VANQUISH-2 enrollment completion.

    Browse the Peptx catalogue

    Independently tested compounds, typically 99%+ purity (HPLC), factory-direct pricing. UK stock dispatches within 24 hours.

    Browse UK stock See our tested compounds

    Sold strictly for laboratory research. Not for human consumption.

    Related Articles

    Retatrutide Phase 3 Data: What Triple-Agonist Results Mean for GLP-1 Research

    Eli Lilly's triple-agonist compound Retatrutide has produced the most significant weight reduction data of any investigational peptide to date. Here is what the Phase 3 trial data shows and why researchers are paying attention.

    Tirzepatide Cardiovascular Outcomes: SURMOUNT-MMO Trial Results and Implications

    The SURMOUNT-MMO trial is the first dedicated cardiovascular outcomes study for Tirzepatide. Early results suggest the dual GIP/GLP-1 agonist may reduce major adverse cardiac events in patients with obesity.